StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a report released on Wednesday. The brokerage set a “sell” rating on the stock.
Separately, Needham & Company LLC reissued a “buy” rating and set a $4.25 price objective on shares of OncoCyte in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, OncoCyte presently has a consensus rating of “Hold” and a consensus price target of $4.06.
Get Our Latest Stock Report on OCX
OncoCyte Price Performance
About OncoCyte
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Recommended Stories
- Five stocks we like better than OncoCyte
- 3 Warren Buffett Stocks to Buy Now
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- Consumer Discretionary Stocks Explained
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- How Can Investors Benefit From After-Hours Trading
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.